Free University & Tech Transfer generator
University-Startup Life Science License Term Sheet (TTO)
A non-binding term sheet between a university Technology Transfer Office and a startup licensee outlining the commercial framework for an exclusive or non-exclusive license to life-science intellectual property, including field, territory, diligence milestones, financial terms, and reserved rights.
What is a University-Startup Life Science License Term Sheet?
A University-Startup Life Science License Term Sheet (TTO) is the non-binding term sheet a university Technology Transfer Office and a startup licensee sign to set the commercial framework for an exclusive or non-exclusive license to life-science intellectual property. It covers field, territory, diligence milestones, financial terms, and reserved rights.
Built for University TTOs and early-stage life-science startups (therapeutics, diagnostics, medical devices) negotiating the framework for a definitive license agreement, typically prior to or contemporaneous with the startup's seed or Series A financing.
University-Startup Life Science License Term Sheet template, current for 2026
It reflects the post-Loper Bright regulatory-deference realities for FDA/BLA pathways and the updated Bayh-Dole march-in framing that followed the 2024 NIST guidance and 2025 revisions. The tiered sublicense revenue share is calibrated to modern platform-therapeutic economics. It carries express carve-outs for AI-assisted discovery inventorship (post-Thaler/DABUS), express treatment of cell/gene therapy modalities and companion diagnostics, and an equity anti-dilution formulation aligned with 2025-2026 seed/Series A market terms.
How HDAi does this differently
Unlike a static form, HDAi runs a guided interview and assembles your University-Startup Life Science License Term Sheet as you answer. When you want it finished, a licensed Hart David Carson attorney reviews it and tailors it to your facts before you sign. The interview and the first draft are automated. The judgment belongs to an attorney.
What you’ll be asked
A short interview in plain language that asks only what this document needs.
- Effective date of this term sheet The date the parties intend the non-binding framework to be effective. The definitive license agreement will be dated separately.
- Full legal name of the university (Licensor) Use the exact legal name of the contracting entity, often a board of regents or trustees, rather than the university's d/b/a. The TTO signs on its behalf.
- Name of the Technology Transfer Office The office administering the license on behalf of the university. Used in the notice block.
- University's state of organization / principal location
- Full legal name of the startup licensee
- Licensee's state of incorporation
- Short name of the licensed technology A one-line handle used throughout the document (e.g., 'the Compound', 'the Platform').
- Describe the licensed technology and the specific inventions Identify the invention disclosure numbers, lab of origin, and any federal funding source (this triggers Bayh-Dole).
- List the licensed patents, applications, and known family members Include provisionals, non-provisionals, PCTs, and foreign counterparts known at signing. A definitive Exhibit A will be attached to the license agreement.
- Does the license include know-how and materials? Life-science deals almost always include know-how; if biological materials (cell lines, plasmids, vectors) transfer, they are usually governed by a separate MTA incorporated by reference.
- Field of use Be specific about indication, modality, and (if applicable) route of administration. Overbroad fields are the most common cause of failed TTO negotiations.
- Territory
- Exclusivity Exclusivity is the dominant commercial variable. Exclusive licenses require firm diligence milestones; non-exclusive licenses typically carry lower royalties but no diligence ladder.
- Was the technology developed with federal funding (Bayh-Dole subject)? Federally funded inventions carry a non-transferable government license and are subject to march-in rights under 35 U.S.C. Sec. 203. The 2024 NIST framework and 2025 revisions clarified but did not eliminate march-in.
- Upfront license issuance fee (USD) Cash payable at execution of the definitive license, typically $50K-$500K for early-stage life-science deals.
- Annual license maintenance fee (USD, creditable against royalties) Typically $10K-$100K per year, escalating, creditable against earned royalties in the same year.
- Equity grant to the university (fully diluted % at signing) Common range is 2%-8% of the fully diluted post-money capitalization at closing of the license, often with participation rights through a Qualified Financing.
- Qualified Financing threshold triggering anti-dilution end (USD) The equity grant is typically non-dilutable until the startup raises a Qualified Financing of at least this size (usually Series A or first priced round above $10M-$25M).
- Tier 1 royalty on the first $100M of annual Net Sales (%) Life-science royalties are typically 2%-8% on small molecules, 1%-5% on biologics, 3%-10% on diagnostics, and 4%-15% on cell/gene therapies.
- Tier 2 royalty on annual Net Sales above $100M and up to $500M (%)
- Tier 3 royalty on annual Net Sales over $500M (%)
- Anti-stacking royalty-offset cap (maximum % reduction of earned royalties for third-party licenses) Optional. If Company must take third-party licenses to practice, it may credit a share of those royalties against amounts owed University, subject to a floor. State the maximum percentage by which any quarter's earned royalty may be reduced (commonly 50%). Leave blank to omit the offset.
- Minimum annual royalty (beginning in year of first commercial sale) (USD)
- Sublicense revenue share on sublicenses granted before IND acceptance (%) Sublicense income share is tiered by the clinical stage at which the sublicense is granted. Typical ranges are 20%-35% pre-IND, 15%-25% in Phase 1, 10%-20% in Phase 2, and 8%-15% from Phase 3 onward.
- Sublicense revenue share on sublicenses granted from IND acceptance through Phase 1 (%)
- Sublicense revenue share on sublicenses granted at Phase 2 or later (%)
- Milestone payment on IND acceptance (USD)
- Milestone payment when the first patient is dosed in Phase 1 (USD) The first-in-human dosing milestone. This rung matches the Phase 1 diligence obligation and the step-up in required insurance coverage.
- Milestone payment when the first patient is dosed in Phase 2 (USD)
- Milestone payment when the first patient is dosed in Phase 3 (USD)
- Milestone payment on BLA/NDA acceptance (USD)
- Milestone payment on first regulatory approval in a Major Market (USD)
- Diligence milestone to close a financing of at least (USD) within (months from Effective Date) The first diligence rung is typically a seed or Series A financing benchmark.
- Diligence deadline to file the IND (months from Effective Date)
- Diligence deadline to dose the first patient in Phase 1 (months)
- Diligence deadline to initiate Phase 2 (months)
- Diligence deadline to obtain first regulatory approval (months)
- Pre-clinical floor for combined general and product liability coverage (per occurrence, USD) The baseline coverage Company must carry before any human dosing. Common range is $1M-$2M per occurrence / $2M-$3M aggregate.
- Coverage step-up from first human dosing (per occurrence, USD) Coverage steps up before the first patient is dosed in any clinical trial. Common range is $3M-$5M per occurrence.
- Coverage step-up from First Commercial Sale (per occurrence, USD) Product-liability coverage steps up again at commercial launch. Common range is $5M-$10M+ per occurrence.
- Who controls patent prosecution?
- Publication review period (days for licensee to review before submission) Standard university practice permits a 30-90 day review to allow patent filings, but the university cannot indefinitely delay academic publication.
- Dispute resolution mechanism Universities frequently insist on their home-state courts; startups often prefer confidential arbitration. Escalated mediation-then-arbitration is common for cross-border or high-value life-science deals.
- Arbitration administrator and seat Name the administering body and the seat, for example JAMS in San Francisco under its Comprehensive Arbitration Rules, or the ICC or the AAA-ICDR for a cross-border license.
- Assignment fee on a permitted change-of-control assignment (USD, optional) Optional. Some TTOs charge a modest fee (often $25K-$100K, or a small percentage of consideration) when the license is assigned in a change of control. Leave blank to omit.
- Term in years after First Commercial Sale (the license runs to the later of that date or the last-to-expire licensed patent)
- Governing law Universities generally require their home-state law; startups may negotiate for Delaware if the university will accept it.
- Is the confidentiality section binding notwithstanding non-binding nature?
- Negotiation exclusivity period (days) During this period the university will not negotiate a competing license within the same field.
Frequently asked
About the University-Startup Life Science License Term Sheet and how HDAi works.
What is a University-Startup Life Science License Term Sheet (TTO)? +
A University-Startup Life Science License Term Sheet (TTO) is a non-binding term sheet between a university Technology Transfer Office and a startup licensee. It outlines the commercial framework for an exclusive or non-exclusive license to life-science intellectual property, including field, territory, diligence milestones, financial terms, and reserved rights. University TTOs and early-stage life-science startups (therapeutics, diagnostics, medical devices) use it to negotiate the framework for a definitive license agreement, typically before or alongside the startup's seed or Series A financing.
Is HDAi's University-Startup Life Science License Term Sheet (TTO) legally binding? +
A term sheet is generally non-binding on the economic terms and binding only in the provisions it marks as binding, typically confidentiality, exclusivity, expenses and governing law. The definitive agreements that follow are what bind the parties; have a licensed Hart David Carson attorney draft or review those before you sign.
Do I need a lawyer to use this University-Startup Life Science License Term Sheet (TTO)? +
You can generate and download the University-Startup Life Science License Term Sheet (TTO) in minutes, free of charge. A licensed Hart David Carson attorney can then review it and tailor it to your facts before you sign, which is the part no template can do.
What makes this University-Startup Life Science License Term Sheet (TTO) current for 2026? +
Its regulatory framing reflects the post-Loper Bright deference realities for FDA/BLA pathways, and its Bayh-Dole march-in language follows the 2024 NIST guidance and the 2025 revisions. Sublicense revenue share is tiered and calibrated to modern platform-therapeutic economics, AI-assisted discovery inventorship has express carve-outs (post-Thaler/DABUS), cell/gene therapy modalities and companion diagnostics get express treatment, and the equity anti-dilution formulation is aligned with 2025-2026 seed/Series A market terms.
How long does the University-Startup Life Science License Term Sheet (TTO) take? +
Estimated time about 25 min (49 questions), depending on how much you already know. The document assembles as you answer. Export it as PDF or Word, or send it to a Hart David Carson attorney for review.
Does this University-Startup Life Science License Term Sheet (TTO) work in my state? +
HDAi's interview is state-aware. If you ask an attorney to finish the draft, a licensed Hart David Carson attorney confirms it against your state's requirements before you rely on it. Validity and required formalities vary by state.
Related documents
More in University & Tech Transfer.
University & Tech Transfer
Related generators
US-BOLT Life Science License Agreement (University to Startup) · University Climate Tech License Term Sheet · All 124 →